(Editor's Note: This article, which was originally published on July 11, 2002, incorrectly stated that the short-term ratings were remaining on CreditWatch. The short-term ratings were affirmed and are not on Credit Watch. A corrected version follows.) On July 12, 2002, Standard&Poor's reported that its 'AAA' corporate credit and long-term debt ratings on pharmaceutical company Bristol-Myers Squibb Co. remain on CreditWatch, with negative implications, pending a review of the company's earnings growth prospects over the next several years. At the same time, Standard&Poor's affirmed its 'A-1+' short-term corporate credit and commercial paper ratings on Bristol-Myers Squibb. This announcement followed Bristol-Myers Squibb's confirmation that it has been in discussions since April 2002 with the Securities and Exchange
